Conferences
ASCO GU 2025: Real-World Time on Treatment with First-Line Enfortumab Vedotin and Pembrolizumab After U.S. FDA Approval for Advanced Urothelial Cancer
February 15, 2025
ASCO GU 2025: Clinical Efficacy of Enfortumab Vedotin + Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma: A Real-World Retrospective Study
February 15, 2025
ASCO GU 2025: Clinically Advanced Urothelial Bladder Cancer in Young Onset Bladder Cancer (YOUC) Patients: A Genomic Landscape Study
February 15, 2025
ASCO GU 2025: A Phase 2 Trial of Risk Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for Muscle-Invasive Bladder Cancer (RETAIN-2)
February 15, 2025
ASCO GU 2025: Datopotamab Deruxtecan (Dato-DXd) in Locally Advanced/metastatic Urothelial Cancer: Updated Results from the Phase 1 TROPION PanTumor01 Study
February 15, 2025
ASCO GU 2025: Treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer With UGN-102: Results of the Phase 3 ATLAS and ENVISION Studies
February 15, 2025
ASCO GU 2025: Discussant: Adjuvant Immunotherapy in High Risk Muscle Invasive Bladder Cancer
February 15, 2025